Document Detail

Retinal function in rabbits does not improve 4-5 months after terminating treatment with vigabatrin.
MedLine Citation:
PMID:  16633724     Owner:  NLM     Status:  MEDLINE    
PURPOSE: We have previously reported changes in retinal function and histopathology in rabbits treated with vigabatrin. The purpose of the present study was to evaluate retinal function and histopathology of retina in rabbits 4-5 months after terminating vigabatrin medication. METHODS: Five rabbits were treated with a daily per oral dose of vigabatrin during 12-13 months. After terminating treatment an observation period of 4-5 months followed. Six rabbits receiving water served as controls. Standardized full-field electroretinograms were performed every 6-8 weeks, using a Burian-Allen bipolar contact lens. After 18 months the rabbits were sacrificed and the morphology of the sectioned retina was studied. The antibodies used for staining were GABA, GFAP, GAD, and vimentin. RESULTS: After 12-13 months of treatment the full-field ERG was reduced in all rabbits treated with vigabatrin. There was a statistically significant difference in the dark adapted cone b-wave amplitude between treated animals and controls (Wilcoxon signed-rank test, p = 0.043). This difference was consistent also 4-5 months after terminating treatment. Immunohistology of the sectioned retina demonstrated no significant difference in immunoreactivity between treated animals and controls. All treated rabbits demonstrated elevated serum concentration of the drug during medication. CONCLUSION: Four to five months after terminating treatment with vigabatrin the rabbit full-field ERG remains reduced in isolated cone b-wave amplitude indicating that vigabatrin induced retinal dysfunction may be irreversible. However, immunohistology is normal after a period without treatment, implying that the previously described changes in retinal morphology and glial cell activity are reversible, and probably exist only during treatment.
Ulrika Kjellström; Sten Kjellström; Anitha Bruun; Sten Andréasson; Vesna Ponjavic
Related Documents :
19700194 - Primary end point (six months) results of the ranibizumab for edema of the macula in di...
23888044 - Improving survival rates of patients with idiopathic dilated cardiomyopathy in tuscany ...
18301034 - Surgical drainage of chronic serous retinal detachment associated with uveitis.
19643484 - Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherap...
8921924 - Low dose cyclosporine in early rheumatoid arthritis: effective and safe after two years...
629674 - Treatment of intermittent exotropia.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Documenta ophthalmologica. Advances in ophthalmology     Volume:  112     ISSN:  0012-4486     ISO Abbreviation:  Doc Ophthalmol     Publication Date:  2006 Jan 
Date Detail:
Created Date:  2006-04-24     Completed Date:  2006-12-05     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0370667     Medline TA:  Doc Ophthalmol     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  35-41     Citation Subset:  IM    
Dept. of Ophthalmology, University of Lund, Lund, S 221 85, Sweden.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Oral
Anticonvulsants / administration & dosage,  pharmacokinetics,  therapeutic use*
Disease Models, Animal
Electroretinography / drug effects
Follow-Up Studies
Retina / drug effects,  pathology,  physiopathology*
Seizures / blood,  drug therapy,  physiopathology
Vigabatrin / administration & dosage,  pharmacokinetics,  therapeutic use*
Visual Fields / drug effects,  physiology*
Reg. No./Substance:
0/Anticonvulsants; 60643-86-9/Vigabatrin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Vitamin A deficiency modifies the mfERG: a case study of rod influence on the mfERG.
Next Document:  Wide field multifocal and standard full field electroretinographic features of hemi retinal vein occ...